Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary Revascularization
- 12 June 1997
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 336 (24) , 1689-1697
- https://doi.org/10.1056/nejm199706123362401
Abstract
Blockade of the platelet glycoprotein IIb/IIIa receptor with abciximab (a monoclonal-antibody Fab fragment directed against the receptor) has been shown to diminish ischemic complications among patients undergoing high-risk coronary angioplasty or atherectomy but increases bleeding complications. The widespread applicability of this treatment is unknown, particularly in view of the observed risk of hemorrhage.Keywords
This publication has 23 references indexed in Scilit:
- Post-intervention cardiac enzyme elevations: Prognostic significance in IMPACT IIJournal of the American College of Cardiology, 1996
- Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: Insights from the coronary angioplasty versus excisional atherectomy trial (CAVEAT)Journal of the American College of Cardiology, 1995
- Randomized prospective evaluation of prolonged versus abbreviated intravenous heparin therapy after coronary angioplastyJournal of the American College of Cardiology, 1994
- The use of activated clotting times to monitor heparin therapy during and after interventional proceduresClinical Cardiology, 1994
- Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six monthsThe Lancet, 1994
- Peripheral vascular complications of coronary angioplasty by the femoral and brachial techniquesCatheterization and Cardiovascular Diagnosis, 1994
- Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparinCatheterization and Cardiovascular Diagnosis, 1992
- The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplastyAmerican Heart Journal, 1992
- Postcatheterization vascular complications associated with percutaneous transluminal coronary angioplastyJournal of Vascular Surgery, 1990
- Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinaseJournal of the American College of Cardiology, 1988